SG11202108900WA - Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer - Google Patents
Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancerInfo
- Publication number
- SG11202108900WA SG11202108900WA SG11202108900WA SG11202108900WA SG11202108900WA SG 11202108900W A SG11202108900W A SG 11202108900WA SG 11202108900W A SG11202108900W A SG 11202108900WA SG 11202108900W A SG11202108900W A SG 11202108900WA SG 11202108900W A SG11202108900W A SG 11202108900WA
- Authority
- SG
- Singapore
- Prior art keywords
- azetidobenzodiazepine
- dimers
- conjugates
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000539 dimer Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1903541.9A GB201903541D0 (en) | 2019-03-15 | 2019-03-15 | Compounds and conjugates |
GBGB2000121.0A GB202000121D0 (en) | 2020-01-06 | 2020-01-06 | Compounds and conjugates |
PCT/EP2020/056761 WO2020187721A1 (en) | 2019-03-15 | 2020-03-13 | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202108900WA true SG11202108900WA (en) | 2021-09-29 |
Family
ID=69845376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202108900WA SG11202108900WA (en) | 2019-03-15 | 2020-03-13 | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220160881A1 (en) |
EP (1) | EP3938372B1 (en) |
JP (1) | JP2022524880A (en) |
KR (1) | KR20210139270A (en) |
CN (1) | CN113631560A (en) |
AU (1) | AU2020242747A1 (en) |
BR (1) | BR112021018260A2 (en) |
CA (1) | CA3130174A1 (en) |
ES (1) | ES2967878T3 (en) |
IL (1) | IL286326A (en) |
MX (1) | MX2021010477A (en) |
SG (1) | SG11202108900WA (en) |
WO (1) | WO2020187721A1 (en) |
ZA (1) | ZA202105931B (en) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
PT1413582E (en) | 1998-08-27 | 2006-07-31 | Spirogen Ltd | PYRROLOBENZODIAZEPINAS DIMERICAS |
GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
SI1720881T1 (en) | 2004-03-01 | 2013-04-30 | Spirogen Sarl | 11-hydroxy-5h-pyrrolos2,1-ccs1,4cbenzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins |
WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
NZ563136A (en) | 2005-04-21 | 2009-11-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
ATE527262T1 (en) | 2006-01-25 | 2011-10-15 | Sanofi Sa | NEW CYTOTOXIC AGENTS CONTAINING TOMAYMYCIN DERIVATIVES |
PE20090245A1 (en) | 2007-05-08 | 2009-03-17 | Genentech Inc | ANTI-MUC16 ANTIBODIES DESIGNED WITH CYSTEINE AND CONJUGATES OF ANTIBODIES AND DRUGS |
WO2009052249A1 (en) | 2007-10-19 | 2009-04-23 | Genentech, Inc. | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
AU2011239522B2 (en) * | 2010-04-15 | 2014-10-23 | Medimmune Limited | Targeted pyrrolobenzodiazapine conjugates |
PE20130342A1 (en) | 2010-04-15 | 2013-04-20 | Spirogen Sarl | PIRROLOBENZODIACEPINES AND CONJUGATES OF THE SAME |
DK2906251T3 (en) * | 2012-10-12 | 2017-11-20 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-CD22-antibody conjugates |
PL2766048T3 (en) | 2012-10-12 | 2015-05-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
KR20180019592A (en) | 2015-06-23 | 2018-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | Macrocycline benzodiazepine dimer, conjugate thereof, preparation method and uses |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
MA50059A (en) | 2016-11-10 | 2019-09-18 | Medimmune Llc | SPECIFIC BINDING MOLECULES OF ASCT2 AND THEIR USES |
EP3612537B1 (en) * | 2017-04-18 | 2022-07-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
-
2020
- 2020-03-13 US US17/439,639 patent/US20220160881A1/en active Pending
- 2020-03-13 SG SG11202108900WA patent/SG11202108900WA/en unknown
- 2020-03-13 CN CN202080021224.4A patent/CN113631560A/en active Pending
- 2020-03-13 ES ES20711857T patent/ES2967878T3/en active Active
- 2020-03-13 BR BR112021018260A patent/BR112021018260A2/en unknown
- 2020-03-13 WO PCT/EP2020/056761 patent/WO2020187721A1/en unknown
- 2020-03-13 JP JP2021555569A patent/JP2022524880A/en active Pending
- 2020-03-13 KR KR1020217029628A patent/KR20210139270A/en unknown
- 2020-03-13 EP EP20711857.1A patent/EP3938372B1/en active Active
- 2020-03-13 AU AU2020242747A patent/AU2020242747A1/en active Pending
- 2020-03-13 MX MX2021010477A patent/MX2021010477A/en unknown
- 2020-03-13 CA CA3130174A patent/CA3130174A1/en active Pending
-
2021
- 2021-08-18 ZA ZA2021/05931A patent/ZA202105931B/en unknown
- 2021-09-13 IL IL286326A patent/IL286326A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021018260A2 (en) | 2021-11-23 |
MX2021010477A (en) | 2021-10-01 |
CN113631560A (en) | 2021-11-09 |
KR20210139270A (en) | 2021-11-22 |
CA3130174A1 (en) | 2020-09-24 |
EP3938372A1 (en) | 2022-01-19 |
IL286326A (en) | 2021-10-31 |
JP2022524880A (en) | 2022-05-10 |
AU2020242747A1 (en) | 2021-09-16 |
WO2020187721A1 (en) | 2020-09-24 |
US20220160881A1 (en) | 2022-05-26 |
EP3938372B1 (en) | 2023-10-25 |
ZA202105931B (en) | 2024-01-31 |
ES2967878T3 (en) | 2024-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL270814A (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
IL288485A (en) | Anti-trop2 antibody-drug conjugates for use in treating cancer | |
EP3250609A4 (en) | Il13ra alpha 2 binding agents and use thereof in cancer treatment | |
IL266623A (en) | Pharmaceutical composition for use in the therapeutic treatment of cancer and complications of cancer | |
IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
IL280510A (en) | Antibody-drug conjugates for use in the treatment of metastatic brain tumor | |
EP4066837A4 (en) | Use of bi853520 in cancer treatment | |
IL276768A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
IL274122A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
IL280617A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
EP3897725A4 (en) | Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer | |
IL280830A (en) | Conjugates for use in methods of treating cancer | |
IL277854A (en) | Antibody-drug conjugates and their uses for the treatment of cancer | |
IL286334A (en) | Modified micrornas and their use in the treatment of cancer | |
IL304245A (en) | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | |
EP3999092A4 (en) | Combination cancer therapy agents and methods | |
IL269121A (en) | Usl-311 for use in the treatment of cancer | |
IL308058A (en) | Molephantin derivatives useful in the treatment of cancer | |
IL288178A (en) | Gmci and ddri combination therapy for treating cancer | |
IL286326A (en) | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer | |
EP3891123A4 (en) | Oligo-benzamide analogs and their use in cancer treatment | |
IL277038A (en) | Bexarotene derivatives and their use in treating cancer | |
GB201810635D0 (en) | Peptides and cancer treatment | |
IL277112A (en) | Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer | |
GB202317288D0 (en) | Pyrrolopyridone derivatives useful in the treatment of cancer |